You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK)與杭州多禧簽署藥品開發及許可合同
阿思達克 12-04 04:47

君實生物(01877.HK)公布,與杭州多禧簽署藥品開發及許可協議。據此,公司獲得許可使用DAC-002,在授權許可區域(除日本、韓國以外的全部亞洲國家及區域)內負責DAC-002後續的臨床試驗、藥品註冊、商業化生產、銷售及其他商業活動。杭州多禧將獲得3,000萬人民幣(下同)首付款和226.8萬元的樣品製備費用,公司並將按研發進展支付累計不超過2.7億元的研發及上市里程碑款,以及在DAC-002實現商業化銷售後支付年銷售收入6%-10%的收益分成。

DAC-002是抗Trop2單抗通過智能連結體偶聯抗微管蛋白Tubulysin B類似物的藥物,主要用於治療Trop2陽性三陰性乳腺癌、小細胞肺癌、胰腺癌等實體腫瘤。目前已向國家藥品監督管理局申報臨床試驗並獲受理。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account